Intravitreal vascular endothelial growth factor inhibitors did not increase the risk of end-stage renal disease in patients with biopsy-proven diabetic kidney disease based on matched study

Purpose: This study aimed to investigate the effects of intravitreal (IVT) VEGFi on long-term renal outcomes in patients with biopsy-proven diabetic kidney disease (DKD). Patients and methods: Patients prescribed IVT VEGFi (VEGFi group) were enrolled from a retrospective cohort with biopsy-proven DK...

Descripción completa

Detalles Bibliográficos
Autores principales: Xiao, Xiang, Zhang, Junlin, Ji, Shuming, Zou, Yutong, Wu, Yucheng, Qin, Chunmei, Yang, Jia, Zhao, Yuancheng, Yang, Qin, Liu, Fang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9768017/
https://www.ncbi.nlm.nih.gov/pubmed/36569300
http://dx.doi.org/10.3389/fphar.2022.1077047

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9768017/
https://www.ncbi.nlm.nih.gov/pubmed/36569300
http://dx.doi.org/10.3389/fphar.2022.1077047

Ejemplares similares